Pancreatic cells 'remember' cancer-linked epigenetic marks without mutations, study shows
Johns Hopkins Medicine scientists say they have found a pattern of so-called epigenetic "marks" in a transition state between ...
EurekAlert!1d
Pancreatic cells ‘remember’ epigenetic precancerous marks without genetic sequence mutations
Johns Hopkins Medicine scientists say they have found a pattern of so-called epigenetic “marks” in a transition state between ...
Managed Healthcare Executive1d
Trial Supports Bizengri as a Promising Treatment for NRG1 Fusion-Positive Cancers, Including Advanced Lung Cancer
A new study validates NRG1 gene fusions as a targetable driver of advanced NRG1 fusion-positive cancers, adding support for ...
Attralus Presents New Data on Its Pan-Amyloid Diagnostic Candidates at the 2025 American College of Cardiology (ACC) Annual Scientific Session
PET/CT, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis ...
MPR7d
Cabometyx Approved for Advanced Neuroendocrine Tumors
Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.
Medscape9d
FDA OKs Cabozantinib for Pancreatic Neuroendocrine Tumors
Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo.
Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi
Exelixis (EXEL) on Wednesday announced that the Food and Drug Administration has approved cabozantinib, or Cabometyx, for the treatment of ...
Fierce Pharma9d
To approve Exelixis' Cabometyx in neuroendocrine tumors, FDA recognizes 'crossover impact' on survival
After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors. | ...
CURE9d
FDA Approves Cabometyx for Some Neuroendocrine Tumors
The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.
Exelixis gets FDA label expansion for Cabometyx in neuroendocrine tumors
Exelixis (EXEL) wins FDA approval for Cabometyx for advanced pancreatic and extra pancreatic neuroendocrine tumors in ...
Drug Delivery Business11d
Beta Bionics founder talks bringing ‘bionic pancreas’ to market
Beta Bionics recently brought its iLet bionic pancreas to market in 2023 and completed an IPO to become a publicly-traded ...
Hartford Courant15d
Readers speak: We need a warning label in CT for alcohol’s cancer risks
I am also a student in the master of public health program at Bridgeport/Goodwin Universities. As a capstone to my studies, it is my goal to have legislation passed in Connecticut that would ...